VIGIL NEUROSCIENCE INC (VIGL) Fundamental Analysis & Valuation

NASDAQ:VIGL • US92673K1088

Current stock price

8.05 USD
0 (0%)
At close:
8.09 USD
+0.04 (+0.5%)
After Hours:

This VIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VIGL Profitability Analysis

1.1 Basic Checks

  • VIGL had negative earnings in the past year.
  • VIGL had a negative operating cash flow in the past year.
  • In the past 5 years VIGL always reported negative net income.
  • VIGL had a negative operating cash flow in each of the past 5 years.
VIGL Yearly Net Income VS EBIT VS OCF VS FCFVIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -80.94%, VIGL is doing worse than 69.57% of the companies in the same industry.
  • VIGL's Return On Equity of -133.18% is on the low side compared to the rest of the industry. VIGL is outperformed by 60.69% of its industry peers.
Industry RankSector Rank
ROA -80.94%
ROE -133.18%
ROIC N/A
ROA(3y)-54.78%
ROA(5y)-63.89%
ROE(3y)-74.94%
ROE(5y)-84.7%
ROIC(3y)N/A
ROIC(5y)N/A
VIGL Yearly ROA, ROE, ROICVIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • VIGL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIGL Yearly Profit, Operating, Gross MarginsVIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

6

2. VIGL Health Analysis

2.1 Basic Checks

  • VIGL has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for VIGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIGL Yearly Shares OutstandingVIGL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
VIGL Yearly Total Debt VS Total AssetsVIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • VIGL has an Altman-Z score of -1.10. This is a bad value and indicates that VIGL is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -1.10, VIGL perfoms like the industry average, outperforming 58.33% of the companies in the same industry.
  • There is no outstanding debt for VIGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.1
ROIC/WACCN/A
WACCN/A
VIGL Yearly LT Debt VS Equity VS FCFVIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • VIGL has a Current Ratio of 2.97. This indicates that VIGL is financially healthy and has no problem in meeting its short term obligations.
  • VIGL has a Current ratio of 2.97. This is in the lower half of the industry: VIGL underperforms 65.22% of its industry peers.
  • A Quick Ratio of 2.97 indicates that VIGL has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.97, VIGL is not doing good in the industry: 63.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
VIGL Yearly Current Assets VS Current LiabilitesVIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

1

3. VIGL Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 1.42% over the past year.
EPS 1Y (TTM)1.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • VIGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.25% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.49%
EPS Next 2Y4.87%
EPS Next 3Y-1.63%
EPS Next 5Y18.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIGL Yearly Revenue VS EstimatesVIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
VIGL Yearly EPS VS EstimatesVIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

0

4. VIGL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VIGL. In the last year negative earnings were reported.
  • Also next year VIGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIGL Price Earnings VS Forward Price EarningsVIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIGL Per share dataVIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.87%
EPS Next 3Y-1.63%

0

5. VIGL Dividend Analysis

5.1 Amount

  • VIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

VIGL Fundamentals: All Metrics, Ratios and Statistics

VIGIL NEUROSCIENCE INC

NASDAQ:VIGL (8/4/2025, 8:00:01 PM)

After market: 8.09 +0.04 (+0.5%)

8.05

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05
Earnings (Next)11-03
Inst Owners67.08%
Inst Owner ChangeN/A
Ins Owners0.51%
Ins Owner Change0%
Market Cap375.69M
Revenue(TTM)N/A
Net Income(TTM)-86.73M
Analysts52.31
Price Target8.16 (1.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.88%
Min EPS beat(2)-5.67%
Max EPS beat(2)9.42%
EPS beat(4)3
Avg EPS beat(4)6.62%
Min EPS beat(4)-5.67%
Max EPS beat(4)15.41%
EPS beat(8)6
Avg EPS beat(8)7.04%
EPS beat(12)10
Avg EPS beat(12)8.96%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-48.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.95%
EPS NY rev (1m)0%
EPS NY rev (3m)11.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.77
P/tB 5.77
EV/EBITDA N/A
EPS(TTM)-2.09
EYN/A
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.4
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -80.94%
ROE -133.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.78%
ROA(5y)-63.89%
ROE(3y)-74.94%
ROE(5y)-84.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -1.1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)440.01%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
EPS Next Y20.49%
EPS Next 2Y4.87%
EPS Next 3Y-1.63%
EPS Next 5Y18.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.07%
OCF growth 3YN/A
OCF growth 5YN/A

VIGIL NEUROSCIENCE INC / VIGL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VIGIL NEUROSCIENCE INC (VIGL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VIGL.


Can you provide the valuation status for VIGIL NEUROSCIENCE INC?

ChartMill assigns a valuation rating of 0 / 10 to VIGIL NEUROSCIENCE INC (VIGL). This can be considered as Overvalued.


What is the profitability of VIGL stock?

VIGIL NEUROSCIENCE INC (VIGL) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for VIGL stock?

The Earnings per Share (EPS) of VIGIL NEUROSCIENCE INC (VIGL) is expected to grow by 20.49% in the next year.